SiteBridge, partnered with the American Medical Association's Health2047 venture studio, is an integrated research organization with a network of community practices to empower clinical trials in areas that are historically the most vulnerable and the hardest to reach. Our Trial In A Box™ brings the people, process, and technologies to support in the clinic, community, and patients' homes and enables real-world-data (RWD) solutions.

VGSK Technologies Inc is a biotechnology company engaged in innovative drug delivery to improve medicine. We are the first to successfully achieve a sustained delivery for an inhaled steroid to be given as one dose, once a week, via inhalation for the treatment of respiratory disorders. We have recently obtained an IND to initiate clinical trials for our drug ProLung-budesonide. We also have developed sustained delivery systems for other modes of delivery: intranasal, oral, sublingual, skin, and intravenous for several classes of drugs such antibiotics, protease inhibitors, peptides, MPLA (TLR4 agonist) as well as other steroids. VGSK holds several US and international patents for the platform sustained drug delivery systems and drugs. We look forward to discussing with your team what our company has to offer.

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.

CluePoints revolutionizes risk detection and data management, empowering our community to safeguard study outcomes. Utilizing cutting-edge AI, advanced statistics, and machine learning, CluePoints offers a premier platform for all clinical trial phases, enabling organizations to operationalize RBQM, prepare trials for inspection, and meticulously monitor CRO and study team performance for optimal results. For more information, please visit https://cluepoints.com/

Stiris Research is a full-service Clinical Trial Management company specializing in Phase I through IIIB trials. Our PCL program, developed from listening to our stakeholders, lessen the burden for participants, sites, and sponsors. Ask us how we can increase recruitment and retention in your trials. It’s what makes us different. For more information, please visit www.StirisResearch.com

RxE2 powers community-based clinical trials through technology that expands equitable access to research. By enabling community pharmacies to operate as next-generation clinical trial sites, we recruit, engage, and retain patients where they live and receive care, integrating pharmacists into research to accelerate enrollment, improve adherence, and deliver better outcomes. For more information, please visit https://rxe2.com/

Triomics is a provider of a GenAI native cancer data platform. Utilizing their proprietary OncoLLM, a constellation of models and pipelines tailored specifically to the complexities of oncology, they are able to support mission critical tasks such as clinical trial matching, pre-charting and summarization, and data curation for tumor registries and RWE/RWD.

CSSi and Elixia Research, divisions of Elixia Health, deliver integrated solutions for sponsors. CSSi drives patient recruitment with localized outreach and technology , while Elixia Research offers a network of high-performing sites. Independently , they provide sponsors with reliable patients and sites, accelerating enrollment, improving diversity , and reducing trial timelines.

FutureMeds is an independent, fully-owned European Site Network and DCT service provider dedicated to running patient-centric clinical trials and delivering quality data for the world’ s leading Sponsors & CROs. With 28 strategically located sites across 7 European countries, over 220 experienced investigators, and more than 1400 homecare providers, FutureMeds offers site and DCT solutions across most therapeutic areas and provides reliability , efficiency and accuracy to help clients accelerate patient access to new treatments. To learn more, please visit: www.futuremeds.com

AlgiPharma is a clinical stage biopharmaceutical company with a focus on developing its proprietary alginate technology for:

• Delivery platforms for nanoparticles, small and large molecule based drugs.
• Drug conjugates, adding functionality and reducing toxicity of parent compound.
• Stand alone API in disease areas such as cystic fibrosis (Ph 2b), COPD, and infectious diseases. AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

Ventura Solutions is a life sciences consulting partner specializing in combination products. We provide end-to-end expertise across R&D, quality, and regulatory, supporting clients from early clinical development through commercialization. Our services include device strategy, program execution, talent acquisition, executive recruiting, and customized training. Helping clients accelerate development, ensure compliance, and deliver safe and effective products.

Scientist.com is the life-science industry's premier AI-powered marketplace and R&D orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development pipeline by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. For more information, please visit https://scientist.com/